Insider Trading May 4, 2026 06:28 PM

Analog Devices Executive Activity: CEO Vincent Roche Executes Stock Sale via Pre-Set Trading Plan

Transactions include a $3.98 million sale and option exercise amid recent stock performance near 52-week highs.

By Hana Yamamoto ADI
Analog Devices Executive Activity: CEO Vincent Roche Executes Stock Sale via Pre-Set Trading Plan
ADI

Vincent Roche, the Chair and Chief Executive Officer of Analog Devices Inc. (NASDAQ: ADI), has completed a series of transactions involving company common stock. On May 1, 2026, Mr. Roche sold 10,000 shares of the corporation's common stock in a transaction valued at approximately $3,979,100. The shares were liquidated at a price point of $397.91 per share. This specific divestment was carried out under the framework of a 10b5-1 trading plan, which the CEO had previously established on May 23, 2025.Parallel to this sale, Mr. Roche engaged in an acquisition of 10,000 shares of Analog Devices common stock. This acquisition was facilitated through the exercise of non-qualified stock options at a strike price of $94.41 per share, representing a total value of $944,100. These options were fully vested and carry an expiration date of March 11, 2030. Following these movements, Mr. Roche maintains a direct holding of 187,537.875 shares. Furthermore, the Vincent Roche 2024 Grantor Retained Annuity Trust, which was organized on October 3, 2024, holds an indirect position of 23,515 shares.

Key Points

  • Execution of a 10b5-1 trading plan by the CEO for a $3.98 million sale.
  • Strong performance in AI and datacenter segments driving analyst price targets.
  • Significant 103% annual stock return amid semiconductor sector demand.

Analog Devices Inc. (NASDAQ: ADI) recently saw significant insider activity from its top leadership. Vincent Roche, serving as both Chair and CEO, executed a transaction involving the sale of 10,000 shares of common stock on May 1, 2026. The total value realized from this sale was $3,979,100, with each share being sold at a price of $397.91. It is important to note that this sale was conducted in accordance with a 10b5-1 trading plan that Mr. Roche had adopted on May 23, 2025.

In the same window of activity on May 1, 2026, Mr. Roche also acquired 10,000 shares through the exercise of non-qualified stock options. These options were exercised at a cost of $94.41 per share, totaling $944,100. These specific options have reached full vesting and are scheduled to expire on March 11, 2030. As a result of these combined transactions, Mr. Roche's direct holdings in Analog Devices common stock stand at 187,537.875 shares. Additionally, the Vincent Roche 2024 Grantor Retained Annuity Trust, established on October 3, 2024, holds an indirect interest of 23,515 shares.


Market Context and Performance

This executive activity occurs while ADI shares are trading in close proximity to their 52-week high of $408.37. The company has seen a substantial 103% return over the previous year. However, analysis from InvestingPro suggests that the stock may currently be overvalued when compared against its Fair Value. In the broader semiconductor and electronics landscape, Amble Electronics recently noted a record-breaking first quarter, which was fueled by intense shortages in memory chips. According to Kevin Wang, the global vice president of sales at Amble, revenue there rose fivefold year-over-year and saw a 20% to 30% increase quarter-over-quarter. This demand surge was particularly evident in January and February due to supply constraints for Nexperia components and memory products.


Analyst Perspectives

The semiconductor sector remains active with various updates regarding Analog Devices. Several financial institutions have recently adjusted their outlooks:

  • Cantor Fitzgerald has maintained an Overweight rating, citing growth opportunities and cyclical tailwinds, with a target price of $400.
  • TD Cowen increased its price target for the company to $400, pointing toward improved gross margins and strength in datacenter segments.
  • Truist Securities issued a Hold rating while raising its price target to $364, noting the cyclical strength within the business.
  • Piper Sandler also raised its target to $360, attributing this to strong results in the data center and AI segments that exceeded expectations from the Street.

Key Insights

Key Points:

  • Executive Liquidity via Scheduled Plans: The sale was conducted through a 10b5-1 plan, indicating a pre-determined schedule for trading rather than an immediate reaction to market news. This impacts the semiconductor sector by providing clarity on executive compensation management.
  • Sector Growth Drivers: Strong performance in AI and datacenter segments is a recurring theme among analysts (TD Cowen and Piper Sandler), suggesting these sub-sectors are driving valuation in the broader electronics and chip markets.
  • Significant Annual Returns: The 103% return over the past year highlights the intense momentum within the semiconductor industry.

Risks and Uncertainties:

  • Valuation Discrepancies: There is a noted risk regarding valuation, as InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value despite recent highs. This creates uncertainty for investors in the technology sector regarding entry points.
  • Cyclicality: Analysts from Truist Securities and Cantor Fitzgerald both highlight the "cyclical" nature of the business, which implies that current strengths could be subject to broader economic cycles affecting the semiconductor industry.

Risks

  • Potential overvaluation relative to Fair Value as noted by InvestingPro.
  • Dependency on cyclical market trends within the semiconductor industry.

More from Insider Trading

Marcus & Millichap Director Executes Substantial Common Stock Purchase May 4, 2026 Patterson-UTI CEO Executes Multi-Million Dollar Stock Sale Amidst Year-to-Date Surge May 4, 2026 Snowflake Director Michael Speiser Executes $7.18 Million in Stock Sales May 4, 2026 Edwards Lifesciences Executive Executes Stock Transactions Amid Recent Financial Growth May 4, 2026 Entrada Therapeutics President and COO Executes Stock Sale via Rule 10b5-1 Plan May 4, 2026